What is androgen deprivation therapy?
Androgen deprivation therapy (ADT) is a type of hormone therapy for prostate cancer. It lowers the level of testosterone and other male hormones (androgens) in the body, or stops them from acting on cancer cells. Most prostate cancers rely on androgens to grow, so taking them away can shrink the cancer or slow it down for months to years.
ADT is sometimes called hormone treatment, androgen suppression or medical castration. It is usually given as injections or implants every one to six months, or as daily tablets. In the past, it was often given by an operation to remove the testicles, which make most of the body’s testosterone.
ADT is one of the oldest and most effective treatments for prostate cancer. Its discovery in the 1940s, by the surgeon Charles Huggins, earned a Nobel Prize. Today, it is used both to help cure prostate cancer when combined with radiotherapy, and to control cancer that has spread.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of treatment | Hormone therapy |
| Main use | Prostate cancer, especially higher-risk, recurrent or advanced disease |
| How it is given | Injections or implants every 1, 3 or 6 months; some daily tablets |
| Course length | From 4-6 months to 3 years with radiotherapy; often long term for advanced cancer |
| Often combined with | Radiotherapy, newer hormone tablets or chemotherapy |
| Common side effects | Hot flushes, loss of sex drive, erection problems, tiredness, weight gain |
| Long-term risks | Bone thinning, muscle loss, diabetes, heart and blood vessel problems |
2. How it works
Where androgens come from
| Source | Share of androgens | How ADT acts |
|---|---|---|
| Testicles | Around 90-95% | Stopped by LHRH agonists, antagonists or surgery |
| Adrenal glands | A small amount | Targeted by drugs such as abiraterone |
| Cancer cells themselves | Small amounts, increasing in advanced disease | Targeted by newer hormone drugs |
Types of ADT
| Type | Examples | How it works |
|---|---|---|
| LHRH (GnRH) agonists | Goserelin, leuprorelin, triptorelin | Overstimulate the pituitary gland until it stops signalling the testicles; testosterone briefly rises before it falls |
| LHRH (GnRH) antagonists | Degarelix, relugolix | Block the pituitary signal straight away; no initial rise |
| Anti-androgens | Bicalutamide | Block androgens from acting on cancer cells |
| Surgical castration | Bilateral orchiectomy | Removes the main source of testosterone permanently |
The tumour flare
When an LHRH agonist is started, testosterone rises for one to two weeks before it falls. This can briefly worsen symptoms such as bone pain. To prevent it, an anti-androgen tablet is usually taken for a few weeks around the first injection. Antagonists do not cause a flare.
Newer hormone drugs
| Drug | How it works |
|---|---|
| Abiraterone | Blocks androgen production in the adrenal glands and the tumour |
| Enzalutamide, apalutamide, darolutamide | Stronger androgen receptor blockers |
These drugs are given together with ADT, not instead of it.
3. Who it is for
Conditions treated
| Condition | Role of ADT |
|---|---|
| Prostate adenocarcinoma | Combined with radiotherapy for intermediate and high-risk cancer; main treatment for recurrent and advanced cancer |
| Salivary duct carcinoma | Used for advanced tumours that carry androgen receptors |
Situations in prostate cancer
| Situation | Typical use |
|---|---|
| Intermediate-risk localised cancer with radiotherapy | Short course, often about 4-6 months |
| High-risk localised cancer with radiotherapy | Longer course, often 18 months to 3 years |
| Rising PSA after surgery or radiotherapy | Depends on PSA speed and scan findings |
| Metastatic hormone-sensitive cancer | Continuous ADT, usually combined with a newer hormone drug and sometimes chemotherapy |
| Castration-resistant cancer | ADT is continued alongside further treatments |
Radiotherapy may be delivered as external beam treatment, including proton beam therapy in some centres, or as brachytherapy.
When ADT is usually not needed
Men with low-risk prostate cancer under active surveillance, or after successful surgery with no signs of remaining cancer, do not usually need ADT. The side effects outweigh any benefit in these situations.
4. Before treatment
| Step | Why it is done |
|---|---|
| PSA and testosterone levels | Baseline for later comparison |
| Bone density scan | Checks for bone thinning, especially for long-term treatment |
| Blood sugar and cholesterol | ADT can affect metabolism |
| Blood pressure and heart history | ADT may affect heart health |
| Discussion of side effects | Including effects on sex life and mood |
| Exercise plan | Helps prevent muscle and bone loss |
5. What to expect: step by step
| Step | What happens |
|---|---|
| 1. Anti-androgen tablets | If an LHRH agonist is used, tablets often start a week or two before the first injection |
| 2. First injection or implant | Given by a nurse or doctor under the skin of the abdomen or into a muscle |
| 3. Follow-up visit | Usually after about 3 months, with a PSA test |
| 4. Repeat injections | Every 1, 3 or 6 months, depending on the drug |
| 5. Monitoring | Regular PSA, testosterone and other blood tests |
| 6. Combined treatment | Radiotherapy usually starts after 2-3 months of ADT in localised cancer |
| 7. Review | Decision to stop at the planned time, or continue for advanced disease |
Keep a note of your injection dates. Missing or delaying an injection can allow testosterone to rise again.
Intermittent ADT
In some men with rising PSA but no visible spread, ADT may be given in cycles: treatment is stopped once PSA falls very low and restarted when it rises again. This allows testosterone and quality of life to recover between cycles. It is not suitable for everyone.
What the PSA tells you
The PSA blood test is the main way to tell whether ADT is working. In most men, PSA falls steeply within the first few months. A very low PSA is a good sign. A steady rise while testosterone remains low suggests the cancer is becoming resistant, and your team will discuss next steps.
6. Side effects and risks
| Side effect | How common | What helps |
|---|---|---|
| Hot flushes and sweats | Very common | Layered clothing; some medicines can help |
| Loss of sex drive | Very common | Talking with your partner and team |
| Erection problems | Very common | Tablets, injections or devices may help |
| Tiredness | Common | Regular exercise |
| Weight gain and muscle loss | Common | Resistance and aerobic exercise; healthy diet |
| Breast swelling or tenderness | Common with anti-androgen tablets | Preventive radiotherapy or tamoxifen in some men |
| Mood changes and low mood | Common | Support, counselling and exercise |
| Memory or concentration changes | Some men | Usually mild |
| Bone thinning (osteoporosis) | Increases with time | Exercise, calcium, vitamin D and bone-strengthening drugs |
| Diabetes | Increased risk | Regular blood sugar checks |
| Heart and blood vessel problems | Possible increased risk | Blood pressure, cholesterol and lifestyle management |
| Anaemia | Mild, common | Usually no treatment needed |
Heart risk
A review of studies on heart effects found that observational studies consistently link ADT with heart disease, while randomised trials have not shown this as reliably. Among the drugs studied, abiraterone was linked with a higher risk of cardiac problems (Hu et al., 2020).
The role of exercise
A review of exercise for men on ADT found strong evidence that exercise helps prevent loss of muscle mass and strength, eases fatigue and supports physical function. Evidence for improvements in mood, bone health and sexual function was moderate (Edmunds et al., 2020).
7. Results and outlook
| Study | Main finding |
|---|---|
| EORTC trial, locally advanced prostate cancer (415 men) | Adding 3 years of goserelin to radiotherapy improved five-year survival from 62% to 78% (Bolla et al., 2002) |
| Review of metastatic hormone-sensitive prostate cancer | ADT alone is not enough for lasting control; adding a newer hormone drug and/or docetaxel improves survival in several large trials (Hussain et al., 2024) |
Why ADT is combined with radiotherapy
Radiotherapy kills prostate cancer cells more effectively when they are deprived of androgens. Starting ADT a few months before radiotherapy also shrinks the prostate, which can make the treatment area smaller. The EORTC trial was one of the first to show that this combination helps men live longer.
How long does ADT work?
In advanced cancer, ADT usually controls the disease for a number of years, especially when combined with newer drugs. Over time, most cancers find ways to grow despite low testosterone. This stage is called castration-resistant prostate cancer, and other treatments are then added.
8. Recovery and aftercare
Living well on ADT
| Area | Tips |
|---|---|
| Exercise | Aim for regular aerobic exercise and resistance training each week |
| Diet | Balanced diet with enough calcium and vitamin D; limit sugar and processed foods |
| Smoking and alcohol | Stop smoking and keep alcohol within recommended limits |
| Hot flushes | Avoid triggers such as hot drinks, spicy foods and alcohol |
| Relationships | Talk openly with your partner; ask for psychosexual support |
| Mood | Tell your team if you feel low or anxious |
Protecting your bones
Long-term ADT speeds up bone loss and increases the risk of fractures. Weight-bearing exercise, such as brisk walking and resistance training, helps keep bones strong. Your team may recommend calcium and vitamin D supplements. If a bone density scan shows thinning, medicines such as bisphosphonates or denosumab can reduce fracture risk.
Partners and relationships
ADT changes how men feel about sex and intimacy, and partners are often affected too. Many couples find new ways to stay close, with or without sex. Specialist nurses, psychosexual therapists and prostate cancer support groups can help couples talk through these changes.
After stopping ADT
When short-term ADT ends, testosterone usually recovers over 6-12 months, but this can take longer in older men or after long treatment. Some side effects, such as hot flushes and low sex drive, then gradually ease.
Follow-up
| Check | Typical timing |
|---|---|
| PSA | Every 3-6 months |
| Testosterone | When needed to confirm suppression |
| Bone density | Every 1-2 years on long-term ADT |
| Blood sugar, cholesterol and blood pressure | At least yearly |
Feeling like yourself
Some men describe feeling less like themselves on ADT, with lower energy and motivation. These feelings are valid and common. Staying active, keeping up social contacts and hobbies, and talking openly with your team about how you feel can make a real difference.
9. Alternatives
| Alternative | When it is considered |
|---|---|
| Active surveillance | Low-risk localised cancer |
| Radical prostatectomy | Localised cancer in fit men |
| Radiotherapy without ADT | Some lower-risk cancers |
| Bilateral orchiectomy | Permanent alternative to injections; a different operation from radical orchiectomy for testicular cancer |
| Anti-androgen tablets alone | Occasionally, to preserve sexual function, though usually less effective |
| Clinical trials | New hormone and targeted treatments |
Your team can help you weigh the benefits of ADT against its side effects at each stage of treatment.
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is ADT chemotherapy? | No; it is hormone therapy |
| Will I lose my hair? | No; body hair may thin a little |
| Will my sex life change? | Most men have reduced desire and erections; support is available |
| Can I stop the injections? | Only after discussing it with your team |
| Does ADT cure prostate cancer? | Alone, usually not; with radiotherapy it improves cure rates |
| Will I grow breasts? | Some men get breast swelling, especially with anti-androgen tablets |
| Can I still work and exercise? | Yes; exercise is strongly encouraged |
11. Questions to ask your care team
- Why do I need ADT, and for how long?
- Which drug will I have, and how often?
- Should I have a bone density scan?
- What can I do to reduce side effects?
- Will ADT affect my heart or diabetes risk?
- What support is there for sexual changes?
- Will I also need a newer hormone drug or chemotherapy?
Resources
- Bolla, M. et al. (2002) ‘Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial’, The Lancet, 360(9327), pp. 103-106.
- Edmunds, K. et al. (2020) ‘The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review’, Supportive Care in Cancer, 28(12), pp. 5661-5671.
- Hu, J.R. et al. (2020) ‘Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses’, Arteriosclerosis, Thrombosis, and Vascular Biology, 40(3), pp. e55-e64.
- Hussain, M. et al. (2024) ‘Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review’, JAMA Oncology, 10(6), pp. 807-820.
- National Cancer Institute (2026) Hormone Therapy for Prostate Cancer. Available at: https://www.cancer.gov/types/prostate/prostate-hormone-therapy-fact-sheet (Accessed: October 2026).
- National Cancer Institute (2026) Prostate Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.